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Abstract 
 Serotonin is one of the neurotransmitters implicated in normal personality. Many psychobiological models of 
personality include some dimensions related to serotonin. For instance, the harm avoidance dimension of the 
biosocial model developed by Cloninger is related to serotonergic activity. Higher scores on the harm avoidance 
dimension should theoretically reflect increased serotonergic activity. However, correlation studies related 
serotonin activity to harm avoidance dimension have not yielded consistent findings. These controversial results 
are probably related to the complexity of the neurotransmitter systems, and the different assessment techniques 
used in these studies. Finally, recent genetic studies have examined the association between personality 
dimensions and serotonergic receptor polymorphisms with mixed results. Serotonin is not only related to some 
dimensions of normal personality. Several psychopathological disorders are associated with serotonergic 
dysfunction. More particularly, borderline personality disorder (BPD) can be defined by many of the symptoms 
associated with serotonergic dysregulation, including affective lability, suicidal behaviours, impulsivity and loss 
of impulse control. Indeed, several reports have demonstrated the efficacy of selective serotonin re-uptake drugs 
in treating the depressive and impulsive symptoms of patients with BPD. Moreover, some challenge studies have 
reported a lower serotonergic activity in BPD. Because these challenges are not specific, we have assessed the 
serotonergic activity in BPD with the flesinoxan challenge. Preliminary results showed that the prolactine 
responses to flesinoxan were significantly lower in BPD patients compared to those observed in controls. 
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Introduction 
Serotonin is one of the neurotransmitters implicated in normal personality. Many psychobiological models of 
personality include some dimensions related to serotonin. For instance, in the Zuckerman model of personality 
(1), the dimension of impulsive unsocialized sensation seeking (ImpUSS) is negatively correlated with 
serotonergic dimension. Again, the harm avoidance dimension of the biosocial model developed by Cloninger 
(2) is related to serotonergic activity. Serotonin is not only related to some dimensions of normal personality. 
Several psychopathological disorders are associated with serotonergic dysfunction. More particularly, borderline 
personality disorder (BPD) can be defined by many of the symptoms associated with serotonergic dysregulation, 
including affective lability, suicidal behaviours, impulsivity and loss of impulse control. This review presents 
some recent findings on serotonin, personality and BPD. More particularly, this review focuses on the biosocial 
model of Cloninger and on the flesinoxan challenge test. 
Serotonin and personality 
Cloninger and colleagues have proposed a bioso-cial model of personality based on four temperaments (novelty 
seeking, harm avoidance, reward dependence and persistence) and three characters (self-directedness, 
cooperativeness and self-transcendence) (3). Novelty seeking is defined as the tendency to respond actively to 
novel stimuli leading to pursuit of rewards and escape from punishment. Harm avoidance corresponds to the 
tendency toward an inhibitory response to signals of aversive stimuli that lead to avoidance of punishment and 
non-reward. Reward dependence is defined as the tendency for a positive response to signals of reward to 
maintain or resist behavioural extinction. Persistence is described in terms of perseverance despite frustration 
and fatigue. Self-directedness refers to the ability of an individual to control, regulate and adapt his behaviour to 
fit the situation in accord with individually chosen goals and values. Cooperativeness is formulated to account 
for individual differences in identification with and acceptance of other people. Self-transcendence is a 
characteristic associated with spirituality, and refers generally to identification with everything conceived as 
essential and consequential parts of a unified whole. The temperament and character inventory (TCI) is a 226-
item self-questionnaire developed by Cloninger and colleagues to assess the seven dimensions of personality (4). 
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According to this model, three of the four temperaments were associated with a specific central neurotransmitter. 
Novelty seeking was theoretically associated to dopaminergic activity; harm avoidance to serotonergic activity; 
and reward dependence to noradrenergic activity. More particularly, higher scores on the harm avoidance 
dimension should theoretically reflect increased serotonergic activity. This is directly supported by the fact that 
an inverse relationship was noted between aggression and harm avoidance, as well as between aggression and 
central 5-HT functioning (5,6). 
The relationship between harm avoidance and serotonergic activity has been evaluated in several studies. Pfohl 
et al. (7) have described a higher score of the harm avoidance dimension in obsessive-compulsive disorder 
(OCD) patients compared to controls, but without any association between this dimension and platelet 
imipramine binding. In another study, the score of the harm avoidance dimension was higher in a group of 
bulimic women compared to normal women, but the whole blood serotonin levels were not related to this 
dimension (8). In the study by Limson et al. (9) there were no significant correlations between cerebrospinal 
fluid concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid and harm avoidance scores. 
However, given the complexity of the neurotransmitter systems, these studies cannot be considered as evidence 
against a relationship between serotonergic activity and the harm avoidance dimension. In contrast, Nelson and 
Cloninger (10) have demonstrated that harm avoidance and reward dependence scores were found to 
significantly predict the response to the 5-HT2 receptor antagonist and 5-HT reuptake inhibitor antidepressant 
nefazo-done in depressed patients. More recently, Gerra et al. (11) found that harm avoidance scores correlated 
significantly with prolactin (PRL) response to d-fenfluramine in healthy volunteers. 
Recently, our group has developed a serotonergic challenge test using flesinoxan (12). Flesinoxan is a highly 
potent and selective 5-HT1A agonist inducing a significant and dose-dependent release of PRL and Cortisol in 
normal subjects. In contrast, depressed patients exhibited a blunted Cortisol response, and more particularly 
those with a history of suicide attempts. Flesinoxan challenge was a good candidate to assess the relationship 
between harm avoidance and serotonergic activity. In a first study (13), we have reported a positive association 
between the PRL response to flesinoxan and the harm avoidance dimension in a group of depressed patients. 
This result appears consistent in light of the studies noted above. However, a major pitfall of this study was the 
state dependence of harm avoidance dimension in depression. Indeed, as harm avoidance has been shown in this 
and other studies (14,15) to correlate with the severity of depression, the positive relationship between harm 
avoidance and the PRL response to flesinoxan could be due to the depressive status. Therefore, the same design 
has been carried out in a sample of non-depressed subjects (16). This second study ostensibly replicates and 
extends the first one (13) and is consistent with the results of Gerra et al. (11) 
However, an important limitation of these studies is the selective effect of flesinoxan on the 5-HT1A receptors. 
Indeed, the pharmacologically induced PRL response to flesinoxan is an indirect index of serotonergic 
neurotransmission and could involve areas of the brain not related with the neural substrate of harm avoidance 
hypothesized by Cloninger. Moreover, the lack of a placebo-controlled flesinoxan challenge limits the 
conclusions of this study. Therefore, to examine exhaustively the hypothesized link between harm avoidance and 
serotonergic activity, future studies should be conducted using agonist and antagonist serotonergic agents in non-
patient groups. 
The association between serotonergic function and harm avoidance dimension of the Cloninger model was also 
investigated using genetic markers. Indeed, recent genetic studies have examined the association between 
personality dimensions and serotonergic receptor polymorphisms with mixed results. No association was 
observed between individuals grouped by the long and short forms of the serotonin transporter gene and the 
personality dimension of harm avoidance (17). In contrast, an association between harm avoidance and the short 
form of the serotonin transporter gene (5-HTTLPR) has been reported in another study (18). In a recent study, no 
contribution of the 5-HTR2a polymorphism on harm avoidance personality trait emerged (19). 
Serotonin and BPD 
BPD is defined in DSM-IV (20) as 'a pattern of instability in interpersonal relationships, self-image, and affects, 
and marked impulsivity'. The syndrome of BPD may be classified into four groups of symptoms: affective, 
impulsive, ego/interpersonal and psychotic. Several of these symptoms are associated with serotonergic 
dysfunction, and more particularly affective lability, suicidal behaviours and impulsive aggression. Based on this 
statement, serotonin uptake inhibitors were studied openly in BPD patients soon after the release of fluoxetine. 
Three reports have demonstrated the efficacy of fluoxetine in treating the depressive and impulsive symptoms of 
patients with BPD (21-23). However, these studies were not double-blind, which could lead to bias in collecting 
the data. The first double-blind, placebo-controlled study conducted among a small group of BPD patients 
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demonstrated clear efficacy for fluoxetine over placebo along a number of dimensions, including depression, 
anxiety and global function (24). The second controlled fluoxetine study among BPD patients reported 
improvement in a number of symptoms, but this improvement was not statistically significant, except for 
aggression against objects (25). In another controlled trial in 40 out-patients with personality disorders including 
13 with BPD, fluoxetine had an anti-aggressive effect on impulsive aggressive individuals with personality 
disorder including BPD (26). In an open trial with sertraline, significant reduction in irritability and aggression 
were reported in BPD (27). Significant improvement of BPD patients was also reported with venlafaxine (28). 
However, more controlled trials with larger patient populations are necessary to replicate these results. 
Platelet studies have been carried out in BPD to assess the serotonergic function in this disorder. Platelet 5-HT 
was higher in patients with BPD than in non-borderline patients and normal controls, and was positively 
correlated with the disposition to experience anger (29,30). 
Another way to assess further the role of the 5-HT function in BPD is the use of specific pharmacological 
probes. Cocarro et al. (5) administered the non-specific 5-HT releaser/reuptake blocker fenfluramine to patients 
with major depressive disorders and/or personality disorders including BPD and found that PRL response was 
blunted compared to non-borderline personality disorder and normal control subjects, independent of the 
comorbidity of major affective disorder. Moreover, PRL response was negatively correlated with impulsive 
aggression and with history of suicide attempts. In contrast, Martial et al. [31] have reported higher PRL 
response and lower Cortisol response to fenfluramine in five BPD women compared to controls. Recently, Soloff 
et al. (32) performed a study using positron-emission tomography (PET) during a fenfluramine challenge test in 
BPD. The results shown that patients with BPD have lower responses to serotonergic stimulation in areas of 
prefrontal cortex, a region associated with regulation of impulsive behaviour. Hollander et al. (33) found higher 
Cortisol levels and marginally blunted PRL response to the partial 5-HT agonist meta-chlorophenylpiperazine 
(m-CPP) in eight male patients with BPD compared to controls. However, the results among women (four 
subjects) are not significant. This gender difference, as noted by the authors, might be attributable to circulating 
ovarian hormones. The authors also reported that m-CPP induced a distinctive spacy (depersonal-ized/deualized) 
and high (euphoric) behavioural reaction in the patients. The same group found in a larger sample of BPD 
patients a significant association between the presence of a spacy and high behavioural response to m-CPP and 
increased PRL and Cortisol peak on m-CPP challenge (34). In another study with m-CPP, women with a BPD 
diagnosis had PRL and Cortisol blunted responses to this challenge (35). Furthermore, these authors reported a 
significant negative correlation between delta peak PRL values and abuse characteristics, such as the severity 
and duration of physical and sexual abuse. They concluded that the alteration of the serotonergic system was 
probably not related to the BPD diagnosis per se, but to sustained traumatization during childhood. 
Since these challenges are not specific, we have assessed the serotonergic activity in BPD with the flesinoxan 
challenge test. This preliminary study was conducted among 20 BPD patients (14 women) with a mean age of 
30.5 years (SD = 10.2) and 20 healthy volunteers matched for gender with a mean age of 37.9 years (SD = 9.6). 
The age difference between the two groups was significant (Z= -2.27, P = 0.02). The diagnosis of BPD was 
based on the DSM-IV criteria and on the self-questionnaire from the Structured Clinical Interview for DSM-III 
Axis II (SCID-II). According the DSM-IV criteria, 16 BPD patients had a current diagnosis of major depressive 
disorder, and four had an eating disorder. The patients were free of medication at least 2 weeks before the 
challenge. Because of the influence of oestrogen on the prolactin levels during the menstrual cycle, the 
flesinoxan challenge test was performed between the third and the 12th day of the menstrual cycle. The Ethical 
Committee of the University of Liege Medical School approved the protocol and all subjects gave their informed 
consent. There was a significant difference between BPD patients (40627 ± 21042 mlU min/mL) and healthy 
volunteers (75546 ± 46612 mlU min/mL) for PRL response to flesinoxan (Z= -2.92, P = 0.003). Among the 
BPD patients, PRL response to flesinoxan was lower in patients with past history of suicide attempts (N= 8) 
compared to patients with a negative history (P= -3.04, P <0.002). Because flesinoxan stimulates specifically the 
5-HT1A postsynaptic receptors, these results suggest that BPD patients are characterized by lower 5-HT1A 
receptor sensitivity. Overall, this study is consistent with previous studies that have reported lower PRL response 
to serotonergic challenge tests. Some limitations of the study should be acknowledged. First, the lack of a 
placebo-controlled flesinoxan challenge limits the conclusions of this study. Another important limitation of this 
study is the use of a self-report questionnaire to assess Axis II diagnoses. Given the complexity of personality 
pathology, a structured interview schedule would have been preferable. The comorbidity between Axis II and 
Axis I diagnostic limits also the conclusions. The PRL blunted response observed among BPD patients could be 
due to the comorbidity on Axis I, and more particularly with major depressive disorder. However, some studies 
have reported that PRL response to flesinoxan did not differ between depressed patients and controls, but that 
PRL response was lower in a subgroup of depressed patients characterized by past suicidal history (36). A final 
limitation is the lack of behavioural assessment for impulsivity, irritability. 
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Conclusions 
Taken together, the data reported above support the implication of serotonin in both normal and disordered 
personality. More specifically, serotonergic activity is related with the harm avoidance dimension of the model 
developed by Cloninger. However, some results are not consistent with this relationship. This may indicate that 
the relation between serotonin and harm avoidance is indirect, with the contribution of other neurotransmitter 
systems. An alternative hypothesis is the heterogeneity of the subjects included in these studies and the different 
tolls for serotonin assessment. Concerning BPD, the results reported here show a major implication of the 
serotonergic function in the aetiology of this disorder and are consistent with previous studies which linked 
lower serotonergic activity and impulsivity. These findings provide interesting track for the pharmacological 
treatment of this dramatic disorder. However, more controlled studies with larger patients populations are 
necessary to replicate the results of existing research. 
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